Table 3.
The drug resistance profile in different genders and age groups.
| Drug | Sex | Age | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male (N = 1,303) | Female (N = 647) | ≤20 (N = 151) | 21-40 (N = 790) | 41-60 (N = 545) | >60 (N = 464) | |||||||||||||
| Initial treated TB (N = 1,068) | Re-treated TB (N = 235) | Total TB | Initial treated TB (N = 576) | Re-treated TB (N = 71) | Total TB | Initial treated TB (N = 138) | Re-treated TB (N = 13) | Total TB | Initial treated TB (N = 693) | Re-treated TB (N = 97) | Total TB | Initial treated TB (N = 418) | Re-treated TB (N = 127) | Total TB | Initial treated TB (N = 395) | Re-treated TB (N = 69) | Total TB | |
| Amikacin | 5 (0.47%) | 23 (9.79%) | 28 (2.15%) | 4 (0.69%) | 7 (9.86%) | 11 (1.70%) | 3 (2.17%) | 1 (7.69%) | 4 (2.65%) | 2 (0.29%) | 10 (10.31%) | 12 (1.52%) | 3 (0.72%) | 17 (13.39%) | 20 (3.67%) | 1 (0.25%) | 2 (2.90%) | 3 (0.65%) |
| Cycloserine | 28 (2.62%) | 14 (5.96%) | 42 (3.22%) | 10 (1.74%) | 3 (4.23%) | 13 (2.01%) | 6 (4.35%) | 1 (7.69%) | 7 (4.64%) | 16 (2.31%) | 6 (6.19%) | 22 (2.78%) | 9 (2.15%) | 9 (7.09%) | 18 (3.30%) | 7 (1.77%) | 1 (1.45%) | 8 (1.72%) |
| Ethambutol | 18 (1.69%) | 58 (24.68%) | 76 (5.83%) | 8 (1.39%) | 16 (22.54%) | 24 (3.71%) | 6 (4.35%) | 4 (30.77%) | 10 (6.62%) | 9 (1.30%) | 29 (29.90%) | 38 (4.81%) | 8 (1.91%) | 33 (25.98%) | 41 (7.52%) | 3 (0.76%) | 8 (11.59%) | 11 (2.37%) |
| Ethionamide | 10 (0.94%) | 22 (9.36%) | 32 (2.46%) | 4 (0.69%) | 4 (5.63%) | 8 (1.24%) | 2 (1.45%) | 1 (7.69%) | 3 (1.99%) | 6 (0.87%) | 10 (10.31%) | 16 (2.03%) | 5 (1.20%) | 12 (9.45%) | 17 (3.12%) | 1 (0.25%) | 3 (4.35%) | 4 (0.86%) |
| Isoniazid | 138 (12.92%) | 121 (51.49%) | 259 (19.88%) | 60 (10.42%) | 42 (59.15%) | 102 (15.77%) | 16 (11.59%) | 9 (69.23%) | 25 (16.56%) | 83 (11.98%) | 60 (61.86%) | 143 (18.10%) | 51 (12.20%) | 71 (55.91%) | 122 (22.39%) | 48 (12.15%) | 33 (47.83%) | 71 (15.30%) |
| Kanamycin | 8 (0.75%) | 28 (11.91%) | 36 (2.76%) | 4 (0.69%) | 8 (11.27%) | 12 (1.85%) | 5 (3.62%) | 1 (7.69%) | 6 (3.97%) | 1 (0.14%) | 13 (13.40%) | 14 (1.77%) | 4 (0.96%) | 19 (14.96%) | 23 (4.22%) | 2 (0.51%) | 3 (4.35%) | 5 (1.08%) |
| Moxifloxacin | 71 (6.65%) | 88 (37.45%) | 159 (12.20%) | 44 (7.64%) | 29 (40.85%) | 73 (11.28%) | 9 (6.52%) | 3 (23.08%) | 12 (7.95%) | 32 (4.62%) | 39 (40.21%) | 71 (8.99%) | 33 (7.89%) | 55 (43.31%) | 88 (16.15%) | 41 (10.38%) | 20 (28.99%) | 61 (13.15%) |
| Ofloxacin | 72 (6.74%) | 92 (39.15%) | 164 (12.59%) | 46 (7.99%) | 29 (40.85%) | 75 (11.59%) | 9 (6.52%) | 4 (30.77%) | 13 (8.61%) | 34 (4.91%) | 43 (44.33%) | 77 (9.75%) | 32 (7.66%) | 54 (42.52%) | 86 (15.78%) | 43 (10.89%) | 20 (28.99%) | 63 (13.58%) |
| Aminosalicylic acid | 6 (0.56%) | 10 (4.26%) | 16 (1.23%) | 4 (0.69%) | 1 (1.41%) | 5 (0.77%) | 2 (1.45%) | 2 (15.38%) | 4 (2.65%) | 3 (0.43%) | 4 (4.12%) | 7 (0.89%) | 2 (0.48%) | 5 (3.94%) | 7 (1.28%) | 3 (0.76%) | 0 (0.00%) | 3 (0.65%) |
| Rifabutin | 51 (4.78%) | 92 (39.15%) | 143 (10.97%) | 23 (3.99%) | 29 (40.85%) | 52 (8.04%) | 9 (6.52%) | 6 (46.15%) | 15 (9.93%) | 33 (4.76%) | 47 (48.45%) | 80 (10.13%) | 17 (4.07%) | 48 (37.80%) | 65 (11.93) | 15 (3.80%) | 20 (28.99%) | 35 (7.54%) |
| Rifampin | 65 (6.09%) | 113 (48.09%) | 178 (13.66%) | 27 (4.69%) | 36 (50.70%) | 63 (9.74%) | 11 (7.97%) | 8 (61.54%) | 19 (12.58%) | 37 (5.34%) | 56 (57.73%) | 93 (11.77%) | 23 (5.50%) | 64 (50.39%) | 87 (15.96%) | 21 (5.32%) | 21 (30.43%) | 42 (9.05%) |
| Streptomycin | 129 (12.08%) | 79 (33.62%) | 208 (15.96%) | 68 (11.81%) | 26 (36.62%) | 94 (14.53%) | 17 (12.32%) | 7 (53.85%) | 24 (15.89%) | 90 (12.99%) | 40 (41.24%) | 130 (16.46%) | 47 (11.24%) | 43 (33.86%) | 90 (16.51%) | 43 (10.89%) | 15 (21.74%) | 58 (12.50%) |
| Resistance to any first-line drug | 193 (18.07%) | 141 (60.00%) | 334 (25.63%) | 95 (16.49%) | 44 (61.97%) | 139 (21.48%) | 23 (16.67%) | 9 (69.23%) | 32 (21.19%) | 126 (18.18%) | 64 (65.98%) | 190 (24.05%) | 71 (16.99%) | 81 (63.78%) | 152 (27.89%) | 68 (17.22%) | 31 (44.93%) | 99 (21.34%) |
| Resistance to any drug | 256 (23.97%) | 153 (65.11%) | 409 (31.39%) | 136 (23.61%) | 46 (64.79%) | 182 (28.13%) | 28 (20.29%) | 9 (69.23%) | 37 (24.50%) | 155 (22.37%) | 66 (68.04%) | 221 (27.97%) | 103 (24.64%) | 89 (70.08%) | 192 (35.23%) | 106 (26.84%) | 35 (50.72%) | 141 (30.39%) |
| MDR | 53 (4.96%) | 99 (42.13%) | 152 (11.67%) | 21 (3.65%) | 35 (49.30%) | 56 (8.66%) | 9 (6.52%) | 8 (61.54%) | 17 (11.26%) | 30 (4.33%) | 53 (54.64%) | 83 (10.51%) | 19 (4.55%) | 56 (44.09%) | 75 (13.76%) | 16 (4.05%) | 17 (24.64%) | 33 (7.11%) |
| XDR | 4 (0.37%) | 22 (9.36%) | 26 (2.00%) | 1 (0.17%) | 5 (7.04%) | 6 (0.93%) | 3 (2.17%) | 0 (0.00%) | 3 (1.99%) | 1 (0.14%) | 11 (11.34%) | 12 (1.52%) | 1 (0.24%) | 13 (10.24%) | 14 (2.57%) | 0 (0.00%) | 3 (4.35%) | 3 (0.65%) |